ProNeuro Centrum Medyczne
- Address
- ul. Aleja Zjednoczonej Europy 37, 44-240 Żory, Poland
ProNeuro Centrum Medyczne - Multiple Sclerosis Research Center
ProNeuro Centrum Medyczne is a specialized neurological research facility dedicated to advancing the treatment and understanding of multiple sclerosis (MS). The center focuses on conducting pivotal clinical trials evaluating novel therapeutic approaches and treatment regimens for patients with various forms of MS, with particular expertise in assessing biologic therapies and their administration methods.
- Phase 1-3 trials investigating monoclonal antibody therapies including ocrelizumab and ublituximab for relapsing-remitting multiple sclerosis
- Comparative efficacy and biosimilarity studies evaluating pharmacokinetics, pharmacodynamics, and safety profiles of innovative MS treatments
- Research on optimized drug delivery systems including subcutaneous injection formulations and modified intravenous infusion regimens
The center demonstrates comprehensive capabilities in pharmacokinetic and pharmacodynamic assessment, conducting complex active-controlled trials that require sophisticated imaging analysis of T1 gadolinium-enhancing lesions. With experience spanning early-phase dose-finding studies to large-scale non-inferiority trials, ProNeuro Centrum Medyczne contributes to the development of both novel therapeutics and biosimilar products, ensuring patients have access to effective and safe treatment options for relapsing multiple sclerosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1F. Hoffmann-La Roche AG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG5trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ProNeuro Centrum Medyczne
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis. | Celltrion Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 3 | Unknown | 2024-01-16 | 2026-02-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.